Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Doctors And Software Engineers Pioneer An Advanced Sepsis Detection And Management System
When Jason Martin gives a talk about his research, he begins with the dramatic story of Mariana Bridi da Costa: The young Brazilian supermodel died from severe sepsis in January after amputation of both her hands and feet failed to stop its spread.

Examining The Risk Of Tuberculosis From Arthritis Medication
Treatment with anti-tumor necrosis factor (TNF) agents is recognized as a risk factor for tuberculosis (TB) in patients with immune-mediated inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, Crohn"s disease, psoriatic arthritis and psoriasis. Most TB cases develop as a result of reactivation of a latent TB infection, and health authorities worldwide recommend screening for latent TB and treating patients before initiating anti-TNF treatment. A new study examined cases of TB associated with anti-TNF therapy and found that the risk of TB is higher for patients receiving anti-TNF monoclonal antibody therapy (infliximab or adalimumab) than for those receiving soluble TNF receptor therapy (etanercept). The study is published in the July issue of Arthritis & Rheumatism.
News of the day
Study Identifies How Tamoxifen Stimulates Uterine Cell Growth And Cancer
UCSF researchers have identified a new "feed-forward" pathway linking estrogen receptors in the membrane of the uterus to a process that increases local estrogen levels and promotes cell growth.
Endocrinology

HHS Purchases Additional H1N1 Vaccine Ingredients

HHS Secretary Kathleen Sebelius announced today that the department will commit $884 million to purchase additional supplies of two key ingredients for potential H1N1 vaccine to further prepare the nation for a potential resurgence of the 2009 H1N1 virus. "We recognize that preparedness is shared responsibility between federal, tribal, state, local governments, private organizations and individuals. We are doing our part to be as prepared as possible for the impact that this infectious disease could have on our country," Secretary Sebelius said. "Vaccines may serve an important role in that preparedness. The action we are taking today will provide flexibility in a future immunization program, if a program is recommended." The funds will be used to place additional orders for bulk H1N1 antigen and adjuvant on existing contracts with Sanofi Pasteur, MedImmune, GlaxoSmithKline and Novartis. The vaccine ingredients will become a part of the pandemic stockpile, for use if a vaccination campaign is necessary. Antigen is the active ingredient in a vaccine that causes the human body"s immune system to develop antibodies that help fight an invading virus. Depending on the results of clinical studies, adjuvant could be added to a vaccine to boost the immune system"s response and potentially reduce the amount of antigen necessary for the body to recognize and fight a virus. In May, Secretary Sebelius directed approximately $1 billion to be used for the development of a vaccine and for clinical studies to determine dose level and assess the safety and effectiveness of potential vaccines. The Biomedical Advanced Research and Development Authority (BARDA) in the HHS Office of the Assistant Secretary for Preparedness and Response established the existing contracts with these companies in 2004 as part of the National Strategy for Pandemic Influenza. More information about today"s contract action is available here. For the latest on the 2009 Influenza A H1N1 virus, see http://www.flu.gov. To learn more about the National Strategy for Pandemic Influenza visit http://www.flu.gov/plan/federal/pandemic-influenza.pdf. More about BARDA is available at http://www.hhs.gov/aspr/barda/index.html. HHS


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009